ArticleCardiovascular research2026
Metabolic crisis and TRPM4 activation cause QT prolongation in TANGO2 deficiency disorder.
Article in Cardiovascular research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimsTANGO2 deficiency disorder (TDD), caused by biallelic pathogenic variants in TANGO2, is associated with impaired fatty acid oxidation and metabolic crises that frequently trigger QT prolongation and arrhythmias. The objective was to study the mechanisms responsible for QT prolongation and arrhythmogenesis in TDD. METHODS AND
resultsCRISPR/Cas9 were used to generate human-induced pluripotent stem cell cardiomyocytes (hiPSC-CMs) carrying a TANGO2 exon 3-9 deletion (TANGO2-/-). Bioenergetic function (mitochondrial oxygen consumption rate, intracellular ATP/ADP ratio) and action potentials (APs) were studied under glucose- or palmitate-fueled conditions. This study reports a TDD clinical case of QT prolongation and arrhythmia that responded favourably to L-type calcium channel (LTCC) inhibition with verapamil or vitamin B-complex supplementation. The mechanisms underlying clinical presentations and therapeutic responses were investigated using TANGO2-/- hiPSC-CMs. In glucose-containing medium, the bioenergetic function was comparable between control and TANGO2-/- hiPSC-CMs. In contrast, using palmitate as energy substrate triggered a profound reduction in cellular ATP production rate and decreased ATP/ADP ratios in TANGO2-/- hiPSC-CMs, exacerbated by 24-h fasting. This crisis was prevented by 2-week treatment with vitamins B5 and B9. During the crisis, TANGO2-/- hiPSC-CMs exhibited AP prolongation, prevented by intracellular delivery of Mg-ATP or creatine kinase. LTCC inhibition with verapamil prevented AP prolongation by normalizing ATP/ADP ratios and intracellular Ca mishandling. Importantly, the metabolic crisis upregulated TRPM4, an ATP- and Ca-regulated channel. TRPM4 siRNA knockdown or pharmacological block prevented AP prolongation without rescuing the energetic deficit of TANGO2-/- hiPSC-CMs.
conclusionThese findings suggest a mechanistic link between ATP deficiency, TRPM4 activation, and AP prolongation in TDD. Targeting TRPM4 therapeutically may help prevent QT prolongation and cardiac arrhythmias in TDD crisis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.